Glial Pathology in Bipolar Disorder: Potential Therapeutic Implications

CNS Neuroscience and Therapeutics

Volumn 21, Issue 5, 2015, Pages 393-397

  Dong, Xiao Hua ^a,b   Zhen, Xue Chu ^a  

^a MEDICAL COLLEGE OF SOOCHOW UNIVERSITY   (China)

^b HEBEI NORTH UNIVERSITY   (China)

Author keywords

Antibipolar drugs; Bipolar disorder; Glial cells

Indexed keywords

ANTIDEPRESSANT AGENT; FEZ1 PROTEIN; PROTEIN; PROTEIN S100B; UNCLASSIFIED DRUG;

ALKALINIZATION; ARTICLE; ASTROCYTE; BIPOLAR DISORDER; DISEASE EXACERBATION; GLIA CELL; GLYCOGEN SYNTHESIS; HUMAN; MICROGLIA; NERVE EXCITABILITY; NEUROPROTECTION; OLIGODENDROGLIA; PATHOPHYSIOLOGY; PHENOTYPE; PROTEIN EXPRESSION; SYNAPTIC POTENTIAL; ANIMAL; DRUG EFFECTS; GLIA; PATHOLOGY; PHYSIOLOGY;

ANIMALS; BIPOLAR DISORDER; HUMANS; NEUROGLIA;

EID: 84928056416     PISSN: 17555930     EISSN: 17555949     Source Type: Journal    
DOI: 10.1111/cns.12390     Document Type: Article

References (73)

1. Belmaker RH. Bipolar disorder. N Engl J Med 2004;351:476-486.
2. Machado-Vieira R, Ibrahim L, Zarate CA Jr. Histone deacetylases and mood disorders: epigenetic programming in gene-environment interactions. CNS Neurosci Ther 2011;17:699-704.
3. Fountoulakis KN. Introduction-bipolar illness: current understanding and future perspectives. CNS Neurosci Ther 2012;18:193.
4. Clairembault T, Leclair-Visonneau L, Neunlist M, Derkinderen P. Enteric glial cells: new players in Parkinson's disease? Mov Disord 2014; doi:10.1002/mds.25979. [Epub ahead of print].
5. Rangarajan P, Eng-Ang L, Dheen ST. Potential drugs targeting microglia: current knowledge and future prospects. CNS Neurol Disord Drug Targets 2013;12:799-806.
6. Miao SH, Sun HB, Ye Y, et al. Astrocytic JWA expression is essential to dopaminergic neuron survival in the pathogenesis of Parkinson's disease. CNS Neurosci Ther 2014;20:754-762.
7. Kong H, Zeng XN, Fan Y, et al. Aquaporin-4 knockout exacerbates corticosterone-induced depression by inhibiting astrocyte function and hippocampal neurogenesis. CNS Neurosci Ther 2014;20:391-402.
8. Chakraborty J, Singh R, Dutta D, Naskar A, Rajamma U, Mohanakumar KP. Quercetin improves behavioral deficiencies, restores astrocytes and microglia, and reduces serotonin metabolism in 3-nitropropionic acid-induced rat model of Huntington's disease. CNS Neurosci Ther 2014;20:10-19.
9. Blank T, Prinz M. Microglia as modulators of cognition and neuropsychiatric disorders. Glia 2013;61:62-70.
10. Jin Q, Cheng J, Liu Y, et al. Improvement of functional recovery by chronic metformin treatment is associated with enhanced alternative activation of microglia/macrophages and increased angiogenesis and neurogenesis following experimental stroke. Brain Behav Immun 2014;40:131-142.
11. Ongur D, Drevets WC, Price JL. Glial reduction in the subgenual prefrontal cortex in mood disorders. Proc Natl Acad Sci USA 1998;95:13290-13295.
12. Webster MJ, O'Grady J, Kleinman JE, Weickert CS. Glial fibrillary acidic protein mRNA levels in the cingulated cortex of individuals with depression, bipolar disorder and schizophrenia. Neuroscience 2005;133:453-461.
13. Johnston-Wilson NL, Sims CD, Hofmann JP, et al. Disease-specific alterations in frontal cortex brain proteins in schizophrenia, bipolar disorder, and major depressive disorder. Mol Psychiatry 2000;5:142-149.
14. Watkins CC, Sawa A, Pomper MG. Glia and immune cell signaling in bipolar disorder: insights from neuropharmacology and molecular imaging to clinical application. Transl Psychiatry 2014;4:e350.
15. Rajkowska G, Miguel-Hidalgo JJ. Gliogenesis and glial pathology in depression. CNS Neurol Disord Drug Targets 2007;6:219-233.
16. Rao JS, Harry GJ, Rapoport SI, Kim HW. Increased excitotoxicity and neuroinflammatory markers in postmortem frontal cortex from bipolar disorder patients. Mol Psychiatry 2010;15:384-392.
17. Stertz L, Magalhaes PV, Kapczinski F. Is bipolar disorder an inflammatory condition? The relevance of microglial activation. Curr Opin Psychiatry 2013;26:19-26.
18. Munkholm K, Vinberg M, Vedel Kessing L. Cytokines in bipolar disorder: a systematic review and meta-analysis. J Affect Dis 2013;144:16-27.
19. Soderlund J, Olsson SK, Samuelsson M, et al. Elevation of cerebrospinal fluid interleukin-1ß in bipolar disorder. J Psychiatry Neurosci 2011;36:114-118.
20. Hope S, Dieset I, Agartz I, et al. Affective symptoms are associated with markers of inflammation and immune activation in bipolar disorders but not in schizophrenia. J Psychiatr Res 2011;45:1608-1616.
21. Drexhage RC, Hoogenboezem TH, Versnel MA, Berghout A, Nolen WA, Drexhage HA. The activation of monocyte and T-cell networks in patients with bipolar disorder. Brain Behav Immun 2011;25:1206-1213.
22. Donato R. S100: a multigenic family of calcium-modulated proteins of the EF-hand type with intracellular and extracellular functional roles. Int J Biochem Cell Biol 2001;33:637-668.
23. Zimmer DB, Cornwall EH, Landar A, Song W. The S100 protein family: history, function, and expression. Brain Res Bull 1995;37:417-429.
24. Roche S, Cassidy F, Zhao C, et al. Candidate gene analysis of 21q22: support for S100B as a susceptibility gene for bipolar affective disorder with psychosis. Am J Med Genet B Neuropsychiatr Genet 2007;144B:1094-1096.
25. Gos T, Schroeter ML, Lessel W, et al. S100B-immunopositive astrocytes and oligodendrocytes in the hippocampus are differentially afflicted in unipolar and bipolar depression: a postmortem study. J Psychiatr Res 2013;47:1694-1699.
26. Rothermundt M, Peters M, Prehn JH, Arolt V. S100B in brain damage and neurodegeneration. Microsc Res Tech 2003;60:614-632.
27. Machado-Vieira R, Lara DR, Portela LV, et al. Elevated serum S100B protein in drug-free bipolar patients during first manic episode: a pilot study. Eur Neuropsychopharmacol 2002;12:269-272.
28. Andreazza AC, Cassini C, Rosa AR, et al. Serum S100B and antioxidant enzymes in bipolar patients. J Psychiatr Res 2007;41:523-529.
29. Schroeter ML, Sacher J, Steiner J, Schoenknecht P, Mueller K. Serum S100B represents a new biomarker for mood disorders. Curr Drug Targets 2013;14:1237-1248.
30. Machado-Vieira R, Schmidt AP, Avila TT, et al. Increased cerebrospinal fluid levels of S100B protein in rat model of mania induced by ouabain. Life Sci 2004;76:805-811.
31. Mesman E, Hillegers MH, Ambree O, Arolt V, Nolen WA, Drexhage HA. Monocyte activation, brain-derived neurotrophic factor (BDNF), and S100B in bipolar offspring: a follow-up study from adolescence into adulthood. Bipolar Disord 2015;17:39-49.
32. Tkachev D, Mimmack ML, Ryan MM, et al. Oligodendrocyte dysfunction in schizophrenia and bipolar disorder. Lancet 2003;362:798-805.
33. Ekman CJ, Lind J, Rydén E, Ingvar M, Landén M. Manic episodes are associated with grey matter volume reduction - a voxel-based morphometry brain analysis. Acta Psychiatr Scand 2010;122:507-515.
34. Hajek T, Carrey N, Alda M. Neuroanatomical abnormalities as risk factors for bipolar disorder. Bipolar Disord 2005;7:393-403.
35. Sokolov BP. Oligodendroglial abnormalities in schizophrenia, mood disorders and substance abuse. Comorbidity, shared traits, or molecular phenocopies. Int J Neuropsychopharmacol 2007;10:547-555.
36. Uranova NA, Vostrikov VM, Orlovskaya DD, Rachmanova VI. Oligodendroglial density in the prefrontal cortex in schizophrenia and mood disorders: a study from the Stanley neuropathology consortium. Schizophr Res 2004;67:269-275.
37. Uranova NA, Orlovskaya DD, Vikhreva OV, et al. Electron microscopy of oligodendroglia in severe mental illness. Brain Res Bull 2001;55:597-610.
38. Roy K, Murtie JC, El-Khodor BF, et al. Loss of erbB signaling in oligodendrocytes alters myelin and dopaminergic function, a potential mechanism for neuropsychiatric disorders. Proc Natl Acad Sci USA 2007;104:8131-8136.
39. Savitz JB, Price JL, Drevets WC. Neuropathological and neuromorphometric abnormalities in bipolar disorder: view from the medial prefrontal cortical network. Neurosci Biobehav Rev 2014;42:132-147.
40. Severus E, Schaaff N, Möller HJ. State of the art: treatment of bipolar disorders. CNS Neurosci Ther 2012;18:214-218.
41. Marmol F. Lithium: bipolar disorder and neurodegenerative diseases possible cellular mechanisms of the therapeutic effects of lithium. Prog Neuropsychopharmacol Biol Psychiatry 2008;32:1761-1771.
42. Camins A, Verdaguer E, Junyent F, et al. Potential mechanisms involved in the prevention of neurodegenerative diseases by lithium. CNS Neurosci Ther 2009;15:333-344.
43. Doetsch F, Caille I, Lim DA, Garcia-Verdugo JM, Alvarez-Buylla A. Subventricular zone astrocytes are neural stem cells in the adult mammalian brain. Cell 1999;97:703-716.
44. Brown AM, Ransom BR. Astrocyte glycogen and brain energy metabolism. Glia 2007;55:1263-1271.
45. Cataldo AM, Broadwell RD. Cytochemical identification of cerebral glycogen and glucose-6-phosphatase activity under normal and experimental conditions. II. Choroid plexus and ependymal epithelia, endothelia and pericytes. J Neurocytol 1986;15:511-524.
46. Csutora P, Karsai A, Nagy T, et al. Lithium induces phosphoglucomutase activity in various tissues of rats and in bipolar patients. Int J Neuropsychopharmacol 2006;9:613-619.
47. Hamakawa H, Murashita J, Yamada N, Inubushi T, Kato N, Kato T. Reduced intracellular pH in the basal ganglia and whole brain measured by 31P-MRS in bipolar disorder. Psychiatry Clin Neurosci 2004;58:82-88.
48. Kato T, Murashita J, Kamiya A, Shioiri T, Kato N, Inubushi T. Decreased brain intracellular pH measured by 31P-MRS in bipolar disorder: a confirmation in drug-free patients and correlation with white matter hyperintensity. Eur Arch Psychiatry Clin Neurosci 1998;248:301-306.
49. Song D, Du T, Li B, et al. Astrocytic alkalinization by therapeutically relevant lithium concentrations: implications for myo-inositol depletion. Psychopharmacology 2008;200:187-195.
50. Song D, Li B, Yan E, et al. Chronic treatment with anti-bipolar drugs causes intracellular alkalinization in astrocytes, altering their functions. Neurochem Res 2012;37:2524-2540.
51. Li B, Gu L, Zhang H, et al. Up-regulation of cPLA(2) gene expression in astrocytes by all three conventional anti-bipolar drugs is drug-specific and enzyme-specific. Psychopharmacology 2007;194:333-345.
52. Cunha AB, Frey BN, Andreazza AC, et al. Serum brain-derived neurotrophic factor is decreased in bipolar disorder during depressive and manic episodes. Neurosci Lett 2006;398:215-219.
53. Machado-Vieira R, Dietrich MO, Leke R, et al. Decreased plasma brain derived neurotrophic factor levels in unmedicated bipolar patients during manic episode. Biol Psychiatry 2007;61:142-144.
54. Barbosa IG, Huguet RB, Mendonca VA, et al. Increased plasma levels of brain-derived neurotrophic factor in patients with long-term bipolar disorder. Neurosci Lett 2010;475:95-98.
55. Chen PS, Peng GS, Li G, et al. Valproate protects dopaminergic neurons in midbrain neuron/glia cultures by stimulating the release of neurotrophic factors from astrocytes. Mol Psychiatry 2006;11:1116-1125.
56. Cho KS, Kwon KJ, Choi CS, et al. Valproic acid induces astrocyte-dependent neurite outgrowth from cultured rat primary cortical neuron via modulation of tPA/PAI-1 activity. Glia 2013;61:694-709.
57. Yu Z, Ono C, Kim HB, et al. Four mood stabilizers commonly induce FEZ1 expression in human astrocytes. Bipolar Disord 2011;13:486-499.
58. Fujita T, Maturana AD, Ikuta J, et al. Axonal guidance protein FEZ1 associates with tubulin and kinesin motor protein to transport mitochondria in neurites of NGF-stimulated PC12 cells. Biochem Biophys Res Commun 2007;361:605-610.
59. Ikuta J, Maturana A, Fujita T, et al. Fasciculation and elongation protein zeta-1 (FEZ1) participates in the polarization of hippocampal neuron by controlling the mitochondrial motility. Biochem Biophys Res Commun 2007;353:127-132.
60. Kato T. The role of mitochondrial dysfunction in bipolar disorder. Drug News Perspect 2006;19:597-602.
61. Quiroz JA, Gray NA, Kato T, Manji HK. Mitochondrially mediated plasticity in the pathophysiology and treatment of bipolar disorder. Neuropsychopharmacology 2008;33:2551-2565.
62. Jane DE, Lodge D, Collingridge GL. Kainate receptors: pharmacology, function and therapeutic potential. Neuropharmacology 2009;56:90-113.
63. Li B, Zhang S, Li M, Zhang H, Hertz L, Peng L. Down-regulation of GluK2 kainate receptor expression by chronic treatment with mood-stabilizing anti-convulsants or lithium in cultured astrocytes and brain, but not in neurons. Neuropharmacology 2009;57:375-385.
64. Araque A, Sanzgiri RP, Parpura V, Haydon PG. Calcium elevation in astrocytes causes an NMDA receptor-dependent increase in the frequency of miniature synaptic currents in cultured hippocampal neurons. J Neurosci 1998;18:6822-6829.
65. Parpura V, Baker BJ, Jeras M, Zorec R. Regulated exocytosis in astrocytic signal integration. Neurochem Int 2010;57:451-459.
66. Peng L, Li B, Du T, Wang F, Hertz L. Does conventional anti-bipolar and antidepressant drug therapy reduce NMDA-mediated neuronal excitation by downregulating astrocytic GluK2 function? Pharmacol Biochem Behav 2012;100:712-725.
67. Dityatev A, Rusakov DA. Molecular signals of plasticity at the tetrapartite synapse. Curr Opin Neurobiol 2011;21:353-359.
68. Dityatev A, Fellin T. Extracellular matrix in plasticity and epileptogenesis. Neuron Glia Biol 2008;4:235-247.
69. Wang CC, Chen PS, Hsu CW, Wu SJ, Lin CT, Gean PW. Valproic acid mediates the synaptic excitatory/inhibitory balance through astrocytes-a preliminary study. Prog Neuropsychopharmacol Biol Psychiatry 2012;37:111-120.
70. Lecuona E, Luquin S, Avila J, Garcia-Segura LM, Martin-Vasallo P. Expression of the beta 1 and beta 2(AMOG) subunits of the Na, K-ATPase in neural tissues: cellular and developmental distribution patterns. Brain Res Bull 1996;40:167-174.
71. +-ATPase and endogenous digitalis-like compounds in depressive disorders. Biol Psychiatry 2006;60:491-499.
72. +-ATPase α and β isoforms and FXYD in mice treated chronically with carbamazepine, an anti-bipolar drug. Neurochem Res 2013;38:834-841.
73. Horvat A, Momic T, Petrovic S, Nikezic G, Demajo M. Selective inhibition of brain Na. K-ATPase by drugs. Physiol Res 2006;55:325-338.